These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34800083)

  • 1.
    Yuan S; Zhu Y; Dai Y; Wang Y; Jin D; Liu M; Tang L; Arnesano F; Natile G; Liu Y
    Angew Chem Int Ed Engl; 2022 Jan; 61(4):e202114250. PubMed ID: 34800083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum(IV) Prodrugs.
    Venkatesh V; Sadler PJ
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
    Gibson D
    ChemMedChem; 2021 Jul; 16(14):2188-2191. PubMed ID: 33928760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
    J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.
    Dabbish E; Ponte F; Russo N; Sicilia E
    Inorg Chem; 2019 Mar; 58(6):3851-3860. PubMed ID: 30843385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
    Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
    Sinisi M; Intini FP; Natile G
    Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D
    Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
    Huo S; Shen S; Liu D; Shi T
    J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
    Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
    Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery.
    Ma J; Wang Q; Huang Z; Yang X; Nie Q; Hao W; Wang PG; Wang X
    J Med Chem; 2017 Jul; 60(13):5736-5748. PubMed ID: 28603992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
    Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
    Najjar A; Rajabi N; Karaman R
    Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the acid-base properties of Pt(IV)-diazidodiam(m)inedihyroxido complexes from multinuclear NMR spectroscopy.
    Ronconi L; Pizarro AM; McQuitty RJ; Sadler PJ
    Chemistry; 2011 Oct; 17(43):12051-8. PubMed ID: 21922567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F; Qin X; Xu G; Gou S; Jin X
    Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activity of Pt
    Alonso-de Castro S; Terenzi A; Hager S; Englinger B; Faraone A; Martínez JC; Galanski MS; Keppler BK; Berger W; Salassa L
    Sci Rep; 2018 Nov; 8(1):17198. PubMed ID: 30464209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing platinum azido complexes by 14N and 15N NMR spectroscopy.
    Farrer NJ; Gierth P; Sadler PJ
    Chemistry; 2011 Oct; 17(43):12059-66. PubMed ID: 21922574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.